Prognostic factors in mesothelioma

Lung Cancer

Volumn 49, Issue SUPPL. 1, 2005, Pages

  Steele, Jeremy P C ^a   Klabatsa, Astero ^a   Fennell, Dean A ^a   Palläska, Arben ^a   Sheaff, Mike T ^a   Evans, Marie T ^a   Shamash, Jonathan ^a   Rudd, Robin M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC PROTEIN; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 2; CYTOTOXIC AGENT; EPIRUBICIN; ETOPOSIDE; GLUCOSE TRANSPORTER 1; HEMOGLOBIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN P27; TUMOR MARKER;

ANAMNESIS; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; EPITHELIOID CELL; GENDER; HEALTH CARE ORGANIZATION; HEALTH STATUS; HOSPITAL; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; MALIGNANT MESOTHELIOMA; MEDICAL DECISION MAKING; MEDICAL RECORD; METASTASIS; OBSERVATION; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; STATISTICAL MODEL; SURGICAL ANATOMY; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT PLANNING; UNITED KINGDOM; VALIDATION PROCESS;

EID: 20444388693     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.03.009     Document Type: Article

References (19)

1. J.P. Steele, and R.M. Rudd Malignant mesothelioma: predictors of prognosis and clinical trials Thorax 55 2000 725 726
2. D.A. Fennell, and R.M. Rudd Defective core-apoptosis signaling in diffuse malignant mesothelioma: opportunities for effective drug development Lancet Oncol 5 2004 354 362
3. J.E. Herndon, M.R. Green, A.P. Chahinian, J.M. Corson, Y. Suzuki, and N.J. Vogelzang Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 1998 723 731
4. D. Curran, T. Sahmoud, P. Therasse, J. van Meerbeeck, P.E. Postmus, and G. Giaccone Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience J Clin Oncol 16 1998 145 152
5. G.W. Middleton, I.E. Smith, M.E. O'Brien, A. Norton, T. Hickish, and K. Priest Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma Ann Oncol 9 1998 269 273
6. M.J. Byrne, J.A. Davidson, A.W. Musk, J. Dewar, G. van Hazel, and M. Buck Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study J Clin Oncol 17 1999 25 30
7. J.P. Steele, J. Shamash, M.T. Evans, N.H. Gower, M.D. Tischkowitz, and R.M. Rudd Phase II study of vinorelbine in patients with malignant pleural mesothelioma J Clin Oncol 18 2000 3912 3917
8. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
9. D.A. Fennell, A. Parmar, J. Shamash, M.T. Evans, M.T. Sheaff, and R. Sylvester Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials Lung Cancer 41 Suppl 2 2003 S12
10. J.G. Edwards, K.R. Abrams, J.N. Leverment, T.J. Spyt, D.A. Waller, and K.J. O'Byrne Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems Thorax 55 2000 731 735
11. V. Neumann, A. Rutten, M. Scharmach, K.M. Muller, and M. Fischer Factors influencing long-term survival in mesothelioma patients-results of the German mesothelioma register Int Arch Occup Environ Health 77 2004 191 199
12. D.R. Fitzpatrick, D.J. Peroni, and H. Bielefeldt-Ohmann The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma Am J Respir Cell Mol Biol 12 1995 455 460
13. D.A. Fennell, A. Klabatsa, M.T. Sheaff, J.P. Steele, M.T. Evans, and J.C. Strefford Identification of glucose transporter type 1 overexpression as a predictor of survival in patients with malignant pleural mesothelioma J Clin Oncol 22 14S 2004 7199
14. J.G. Edwards, S.P. Faux, S.M. Plummer, K.R. Abrams, R.A. Walker, and D.A. Waller Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma Clin Cancer Res 8 2002 1857 1862
15. T.W. Beer, P. Shepherd, and N.C. Pullinger p27 immunostaining is related to prognosis in malignant mesothelioma Histopathology 38 2001 535 541
16. M. Bongiovanni, P. Cassoni, P. De Giuli, L. Viberti, S. Cappia, and C. Ivaldi p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma Cancer 92 2001 1245 1250
17. C.E. Comin, C. Anichini, V. Boddi, L. Novelli, and S. Dini MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma Histopathology 36 2000 26 31
18. S. Kumar-Singh, J. Weyler, M.J. Martin, P.B. Vermeulen, and E. Van Marck Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression J Pathol 189 1999 72 78
19. L. Strizzi, R. Muraro, G. Vianale, C. Natoli, L. Talone, and A. Catalano Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival J Pathol 197 2002 218 223